What changed for Chronic Rhinosinusitis

How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.

Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.

• Trials recruiting worldwide 57 to 58 (+1)
• Trials on record 447 to 450 (+3)

Newly subsidised on the PBS

No PBS-reviewed medicines are tracked for Chronic Rhinosinusitis yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.

Past updates

Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.

Recent trend

Recent trial results

The 30 most recent of 63 trials tracked for Chronic Rhinosinusitis that have reported results to a public registry.

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

• NCT04157335 · results posted 19 February 2026

  According to the results reported on ClinicalTrials.gov, this trial (NCT04157335) enrolled 287 adults with chronic rhinosinusitis with nasal polyps — a condition where growths form inside the nose and sinuses, causing blockage and other symptoms. Participants were randomly assigned to receive either benralizumab (144 people) or a placebo (an inactive dummy treatment, 143 people) during a blinded phase lasting about 56 weeks, where neither participants nor their doctors knew who received which. The trial was primarily measuring two things: the size of nasal polyps as seen through a small camera...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04851964 · results posted 27 January 2026

  According to the results reported on ClinicalTrials.gov, this trial (NCT04851964) looked at a medicine called tezepelumab in people with nasal polyps (growths inside the nose that can cause blockage and other symptoms). A total of 203 people received tezepelumab and 205 received a placebo (a dummy treatment with no active ingredient) over 52 weeks. The trial was primarily measuring changes in the size of nasal polyps (using an endoscopy score out of 8) and changes in how blocked participants' noses felt day-to-day. The reported data shows that, after 52 weeks, the nasal polyp score in the tez...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT05672030 · results posted 24 November 2025

  According to the results reported on ClinicalTrials.gov, this trial enrolled 30 people in total, split evenly across three groups of 10: people with a condition called Aspirin-exacerbated Respiratory Disease (AERD, where aspirin triggers breathing or nasal symptoms), people with nasal polyps who can tolerate aspirin (called aspirin-tolerant chronic rhinosinusitis with nasal polyps), and healthy volunteers. All 30 participants completed the study with no drop-outs. The trial was not testing a treatment — instead, it was focused on whether researchers could successfully collect and analyse biolo...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT05878093 · results posted 25 September 2025

  According to the results reported on ClinicalTrials.gov, this trial (NCT05878093) enrolled 63 people in total — 32 received a placebo and 31 received dupilumab (a 300 mg injection given every two weeks). The trial ran for 24 weeks and was measuring changes in nasal polyp size, as well as several symptom scores reported by participants, including nasal congestion, sense of smell, and overall quality of life related to their sinus condition. The reported data shows that for the main measurement — a nasal polyp score rated on a scale of 0 (no polyps) to 8 (most severe) — the placebo group's scor...

  View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT03369717 · results posted 17 June 2025

  According to the results reported on ClinicalTrials.gov, this trial (NCT03369717) enrolled 24 people in total — 12 in a group that received antibiotics after sinus surgery, and 12 in a group that did not receive antibiotics. The trial was looking at whether taking antibiotics after surgery made a difference to rates of post-surgical infection, as well as how participants felt about their sinus-related symptoms and how their sinuses appeared on examination at follow-up visits. The reported data shows that a relatively small number of participants completed the study — 2 in the antibiotics group...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT05198518 · results posted 12 June 2025

  According to the results reported on ClinicalTrials.gov, this trial (NCT05198518) enrolled 60 participants who had recently undergone sinus surgery. They were divided into two groups: 27 people used a microcurrent TENS device (a small device that delivers a very mild electrical current to the skin) and 33 people used a sham device (one that looked the same but did not deliver the active treatment). The trial was measuring post-surgery pain levels and overall sinus-related quality of life over a 14-day period, with participants asked to use their device at least three times a day. The reported...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT05248997 · results posted 26 March 2025

  According to the results reported on ClinicalTrials.gov, this trial (NCT05248997) enrolled 261 people in total — 131 assigned to receive a 75 mg dose of rimegepant and 130 assigned to receive a placebo (a dummy treatment with no active ingredient). Of those, 99 in the rimegepant group and 105 in the placebo group actually received their assigned treatment, and 98 and 104 respectively completed the study. The trial was measuring symptoms of acute sinusitis (sinus pain, pressure, nasal congestion and discharge) using rating scales where participants scored their symptoms from 0 (none) to 10 (wor...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT05035654 · results posted 17 December 2024

  According to the results reported on ClinicalTrials.gov, this trial (NCT05035654) enrolled 48 people across three groups to test a device called LYR-220, which is designed to deliver a medication called mometasone furoate (a type of steroid) into the sinus cavity. Three participants were in a group testing an earlier version of the device (Design 1), 24 were in a group testing a refined version (Design 2), and 21 received a sham (dummy) procedure as a comparison group. The trial was primarily measuring how much of the medication entered the bloodstream, and whether any serious unexpected probl...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT04607005 · results posted 25 November 2024

  According to the results reported on ClinicalTrials.gov, this trial (NCT04607005) enrolled 169 people in total — 84 received mepolizumab and 85 received a placebo (an inactive dummy treatment). The trial ran for 52 weeks and was measuring two main things: the size of nasal polyps (growths inside the nose) as scored by doctors reviewing video recordings of nasal examinations, and how much nasal blockage participants reported in a daily electronic diary. Polyp size was scored on a scale of 0 to 8 (higher = worse), and nasal blockage was rated on a scale of 0 to 10 (higher = worse). The reported...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT05015530 · results posted 8 November 2024

  According to the results reported on ClinicalTrials.gov, this trial enrolled 12 adults who used a hypertonic seawater-based nasal spray called Healsea® Chronic, which also contains a natural extract called Symbiofilm®. All 12 participants completed the study. The trial was measuring changes in the nasal microbiome (the community of bacteria living inside the nose and sinuses) after 30 days of using the spray, as well as participants' quality of life and satisfaction with the product. It is worth noting that only 3 of the 12 participants were included in the strictest analysis group (called the...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT03979209 · results posted 12 August 2024

  According to the results reported on ClinicalTrials.gov, this trial looked at three different doses of a nasal rinse containing mometasone (a steroid medication) — 1 mg, 2 mg, and 4 mg. The trial was measuring whether using this rinse continuously could affect levels of a hormone called cortisol in the blood. Cortisol is a natural hormone your body produces, and when people use steroid-based treatments, one thing researchers sometimes check is whether the body's own cortisol production is being reduced (known as "suppression"). A total of 16 people started and completed the trial — 2 in the 1...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04131686 · results posted 20 February 2024

  According to the results reported on ClinicalTrials.gov, this trial (NCT04131686) involved people being treated at either "Control Sites" or "Test Sites" — 146 people started in the Control group and 148 in the Test group. The vast majority completed the study: 138 in the Control group and 143 in the Test group. The trial was measuring changes in sinus-related symptoms — specifically nasal congestion, nasal or post-nasal discharge, facial pain or pressure, and reduced or lost sense of smell — as rated by an investigator (a clinician, not the patient themselves). Each symptom was scored from 0...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT05049122 · results posted 22 January 2024

  According to the results reported on ClinicalTrials.gov, this trial (NCT05049122) enrolled 25 adults who received injections of dupilumab 300 mg. The trial was measuring changes in nasal polyp size and a range of symptoms — including nasal congestion, loss of smell, and overall symptom burden — in people with chronic rhinosinusitis with nasal polyps (a condition where persistent sinus inflammation causes growths inside the nose). The main study treatment period ran for 24 weeks, with some participants continuing to 52 weeks. Of the 25 who started, 22 completed the full trial. The reported dat...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT03960580 · results posted 21 December 2023

  According to the results reported on ClinicalTrials.gov, this trial (NCT03960580) enrolled 223 adults with chronic rhinosinusitis (long-term sinus inflammation). Participants were randomly assigned to one of three groups: a placebo (inactive treatment), a lower dose of a nasal spray called OPN-375 (186 micrograms twice daily), or a higher dose of OPN-375 (372 micrograms twice daily). The trial measured two main things: how much three key sinus symptoms — nasal congestion, facial pain or pressure, and nasal discharge — changed over four weeks (scored on a combined 0–9 scale, where higher number...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT04041609 · results posted 6 June 2023

  According to the results reported on ClinicalTrials.gov, this trial (NCT04041609) enrolled 71 adults with chronic sinusitis across three groups: 24 received a low dose of LYR-210 (an implantable device placed in the sinuses), 23 received a high dose of LYR-210, and 24 underwent a sham (dummy) procedure for comparison. The trial measured changes in sinusitis symptom scores, quality-of-life questionnaire scores, sinus imaging scores, and the number of participants who experienced side effects thought to be related to the treatment, over a period of up to 24 weeks. Not everyone completed the stud...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT04754230 · results posted 5 April 2023

  According to the results reported on ClinicalTrials.gov, this trial enrolled 40 people in total — 19 in one group and 21 in another. All 40 participants completed the trial with no drop-outs. The trial compared two intravenous (drip) treatments given during or after surgery: a normal saline (salt water) solution, which acted as a placebo (an inactive comparison), and a 1,000 mg dose of tranexamic acid, a medication sometimes used to reduce bleeding. Each day for six days after their procedure, participants rated their own bleeding on a scale from 0 (no bleeding at all) to 10 (uncontrolled blee...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT03055507 · results posted 22 March 2023

  According to the results reported on ClinicalTrials.gov, this trial enrolled 42 people who had undergone nasal surgery — 16 in a control group and 26 in an ibuprofen group. All 42 participants completed the trial with no drop-outs. The trial was measuring post-operative pain levels, nasal bleeding, and the number of opioid (strong painkiller) pills taken each day after surgery. Pain and bleeding were measured using a visual analogue scale — essentially a 10-centimetre line where 0 means none at all and 10 means the worst imaginable. The reported data shows that for post-operative pain, the co...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03673956 · results posted 20 April 2022

  According to the results reported on ClinicalTrials.gov, this trial looked at four different antibiotic nasal saline rinses used to treat sinus infections after surgery. The four groups were: mupirocin, tobramycin, levofloxacin, and vancomycin — each mixed into a saltwater nasal rinse. A total of 19 people started the trial across all four groups (12, 1, 5, and 1 respectively), and 17 completed it. The two who did not finish were both in the mupirocin group. The trial was measuring whether participants developed new antibiotic-resistant organisms (germs that become harder to treat), and also t...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT01955980 · results posted 12 April 2022

  According to the results reported on ClinicalTrials.gov, this trial compared two nasal spray treatments — called "Buparid" (Treatment A) and "Budes" (Treatment B) — in people with inflammation of the nasal passages and sinuses. A total of 19 people took part: 10 in the Buparid group and 9 in the Budes group. All participants who started the trial completed it. The trial measured changes in sinus inflammation using medical imaging scores, self-reported quality of life, and nasal airflow, as well as tracking unwanted side effects. The reported data shows the following numbers. For the main meas...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT01946711 · results posted 12 April 2022

  According to the results reported on ClinicalTrials.gov, this trial involved 14 people in total — 8 in the "Buparid" group (Treatment A) and 6 in the "Budes" group (Treatment B). All 14 participants completed the trial. The study was measuring changes in inflammation of the nasal passages and sinuses, using a scoring system called the Lund-Mackay score (based on MRI scans), where a score of 0 means no impairment and 24 means the most severe impairment. It also looked at side effects, quality of life, and nasal airflow. The reported data shows that, for the primary measure — change in nasal an...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03188822 · results posted 3 December 2021

  According to the results reported on ClinicalTrials.gov, this trial (NCT03188822) enrolled 9 participants, all of whom received a bioabsorbable (dissolving) steroid-releasing sinus implant. The trial was comparing two different dissolving devices placed in the sinuses after surgery — a steroid-releasing sinus stent on one side and a steroid-soaked nasal dressing on the other side — looking at how the sinus opening appeared afterwards. Only 2 of the 9 participants completed the trial, and 7 did not complete it. Because so few participants finished, the reported numbers are based on a very small...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT01214057 · results posted 1 November 2021

  According to the results reported on ClinicalTrials.gov, this trial involved 23 people who were having nasal/sinus surgery. Participants were split into two groups: 12 received total intravenous anaesthesia (all anaesthetic drugs given through a drip) and 11 received inhaled anaesthesia (anaesthetic gases breathed in). The trial was measuring several things during surgery, including how much blood was lost, how clearly the surgeon could see the operating area, how well the blood was clotting (specifically how platelets — the cells that help blood clot — were functioning), and how much blood wa...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT02217332 · results posted 18 May 2021

  According to the results reported on ClinicalTrials.gov, this trial (NCT02217332) enrolled 20 people who all received the study drug dexpramipexole. Of those 20, 13 completed the trial and 7 did not finish. The trial was measuring two main things over six months: changes in the number of a type of white blood cell called eosinophils (cells that can be elevated in certain conditions) circulating in the blood, and changes in the size of nasal polyps (growths inside the nose) as scored by a rating system. Nasal polyp size was rated from 0 to 8, where a lower number means smaller or fewer polyps....

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03478930 · results posted 11 May 2021

  According to the results reported on ClinicalTrials.gov, this trial (NCT03478930) enrolled 249 adults with nasal polyps — 126 who had previously received a placebo in earlier related studies, and 123 who had previously received omalizumab (an injectable medicine). The trial was measuring several things over 24 weeks: the size of nasal polyps (scored on a scale of 0–8), the severity of nasal congestion (scored 0–3 daily by participants), overall nasal symptoms combined into a total score (0–12), and reduced sense of smell (scored 0–3). The trial also tracked how many participants experienced un...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT03599271 · results posted 28 April 2021

  According to the results reported on ClinicalTrials.gov, this trial (NCT03599271) enrolled a total of 75 people across two groups: 70 participants in a "Randomised Cohort," where each person received both a drug-coated balloon device on one side of their nose and a standard (non-drug-coated) balloon device on the other side; and 5 participants in a smaller "PK Cohort" focused on safety and drug levels. The trial was measuring the openness of the frontal sinus ostia (FSO) — the small opening that connects the frontal sinus to the nasal passage — using a specially sized probe and a scoring syste...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT01778465 · results posted 9 March 2021

  According to the results reported on ClinicalTrials.gov, this trial involved 7 participants in total — 3 in one group and 4 in the other. It used a "crossover" design, meaning everyone tried both approaches: one group followed a low-salicylate diet for 7 days first, then switched to a normal diet for 7 days, while the other group did it in the opposite order. Salicylates are natural chemicals found in many foods. The trial was measuring several things in participants' urine, as well as their self-reported sinus and nasal symptoms. The reported data shows the following urine measurements after...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT03661346 · results posted 8 February 2021

  According to the results reported on ClinicalTrials.gov, this trial enrolled 28 people in total — 13 in the esmolol group and 15 in the labetalol group — and all of them completed the study with no drop-outs. Both esmolol and labetalol are medications used during anaesthesia to help control blood pressure and heart rate. The trial was looking at how clearly surgeons could see the operating field during functional endoscopic sinus surgery (FESS, a procedure inside the nose and sinuses), as well as how much blood was lost and what happened to blood pressure and heart rate during the operation....

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03450083 · results posted 22 January 2021

  According to the results reported on ClinicalTrials.gov, this trial (NCT03450083) enrolled 24 people in total — 12 in the benralizumab treatment group and 12 in a placebo (dummy treatment) group. All 24 participants completed the study. The trial was measuring changes in nasal polyp burden and related symptoms over approximately six months, using several scoring tools including scans, smell tests, a symptom questionnaire, and blood tests. The reported data shows the following numbers across the groups. For the main measure — a scoring system for nasal polyp size and number seen on a camera ex...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

• NCT02927834 · results posted 29 December 2020

  According to the results reported on ClinicalTrials.gov, this trial enrolled 24 people across three groups — eight in each group. The three groups were: those who received an antibiotic only, those who received the antibiotic Augmentin combined with a 6-day course of steroids, and those who received Augmentin combined with a 21-day course of steroids. The trial was measuring sinus and nasal symptoms using three tools: a symptom questionnaire (called the SNOT-20), a physical examination of the nasal cavity using a small camera (nasal endoscopy), and a CT scan of the sinuses. By the end of the s...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗

• NCT03705793 · results posted 19 December 2020

  According to the results reported on ClinicalTrials.gov, this trial enrolled 53 people in total — 27 in one group who used a mometasone furoate nasal irrigation (a steroid medication delivered as a rinse through the nose) and 26 in a second group who used a mometasone nasal spray (the same type of steroid delivered as a spray). Of those, 22 and 21 people respectively completed the trial. The trial was measuring changes in sinus and nasal symptoms, participants' own sense of how they responded to treatment, and physical findings seen during a camera examination of the nose. The reported data s...

  Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗

See all 63 reported results for Chronic Rhinosinusitis

These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

What is coming

AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to NIH funding data, a moderate amount of public research money is currently being directed toward Chronic Rhinosinusitis, and encouragingly, that investment has been rising year on year. This upward trend suggests that researchers and funding bodies see value in continuing to explore this condition more deeply. For patients, a growing funding base generally means more studies are being...

See the full Chronic Rhinosinusitis page

Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.